AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16773859 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 15149789 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise training (65-75% HRR, 25-30 min, 3 days/week for 10 months)
Number of subjects: 27
Study 15149789 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise training
Number of subjects: 27
Study 15149789 — intervention group
Group type: COMPARATOR
Intervention: Control group (no change in activity)
Number of subjects: 27
Study 11361264 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide alone (100 mg BD)
Number of subjects: 54
Study 11361264 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of nimesulide (100 mg) and cetirizine (10 mg)
Number of subjects: 54
Study 11361264 — intervention group
Group type: COMPARATOR
Intervention: Cetirizine alone (10 mg)
Number of subjects: 54
Study 9164805 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Well Child Care (GWCC)
Number of subjects: 114
Study 9164805 — intervention group
Group type: COMPARATOR
Intervention: Individual Well Child Care (IWCC)
Number of subjects: 114
Study 8395721 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 20 mg subcutaneously, administered 2 hours before surgery and each morning for 7 postoperative days (morning group)
Number of subjects: 10032
Study 8395721 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 20 mg subcutaneously, administered the evening before surgery and postsurgically for 7 days in the evening (evening group)
Number of subjects: 10032
Study 8395721 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 20 mg
Number of subjects: 10032
Study 3512282 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose budesonide (1600 micrograms per day)
Number of subjects: 45
Study 3512282 — intervention group
Group type: COMPARATOR
Intervention: Conventional dose budesonide (400 micrograms per day)
Number of subjects: 45
Study 3512282 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose budesonide (1600 micrograms per day) during open-label phase
Number of subjects: 45
Study 31327653 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent pneumococcal polysaccharide vaccine (PPSV23)
Number of subjects: 0
Study 31327653 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29706321 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol (150 mg/day)
Number of subjects: 13
Study 29706321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 25341641 — intervention group
Group type: EXPERIMENTAL
Intervention: SHED-IT intervention
Number of subjects: 159
Study 24427264 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based peer support intervention for exclusive breastfeeding, with peer supporters visiting women once antenatally and four times postpartum.
Number of subjects: 0
Study 24427264 — intervention group
Group type: COMPARATOR
Intervention: Operational 'non research' scenario for exclusive breastfeeding promotion.
Number of subjects: 0
Study 22952175 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use supplementary food (RUSF)
Number of subjects: 1125
Study 22952175 — intervention group
Group type: COMPARATOR
Intervention: Corn-soya blend (CSB)
Number of subjects: 1125
Study 18803247 — intervention group
Group type: EXPERIMENTAL
Intervention: High exposure (2126.8 microW/m(2)) and medium exposure (153.6 microW/m(2)) during sessions HM and MH
Number of subjects: 57
Study 18803247 — intervention group
Group type: COMPARATOR
Intervention: Low exposure (5.2 microW/m(2)) during scenario LL
Number of subjects: 57
Study 18077994 — intervention group
Group type: EXPERIMENTAL
Intervention: Liposomal doxorubicin plus bortezomib
Number of subjects: 646
Study 18077994 — intervention group
Group type: COMPARATOR
Intervention: Bortezomib monotherapy
Number of subjects: 646
Study 15366798 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 60
Study 15366798 — intervention group
Group type: COMPARATOR
Intervention: Pethidine 0.8 mg/kg
Number of subjects: 60
Study 11344193 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA 50 mg/day
Number of subjects: 24
Study 11344193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8033847 — intervention group
Group type: EXPERIMENTAL
Intervention: Methanol exposure at 200 ppm for 4 hours
Number of subjects: 26
Study 8033847 — intervention group
Group type: COMPARATOR
Intervention: Control (sham exposure)
Number of subjects: 26
Study 2736882 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid solution supplemented with L‐alanyl‐L‐glutamine (Ala‐Gln) and glycyl‐L‐tyrosine (Gly‐Tyr)
Number of subjects: 6
Study 2736882 — intervention group
Group type: COMPARATOR
Intervention: Control solution supplemented with alanine and glycine
Number of subjects: 6
Study 4881071 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline (3 g or 4 g in one of 3 dose schedules)
Number of subjects: 0
Study 4881071 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol
Number of subjects: 0
Study 4881071 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfaguanidine
Number of subjects: 0
Study 31383649 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab (0.5 mg) administered as 3 monthly intravitreal injections followed by pro re nata at monthly visits
Number of subjects: 100
Study 30222620 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Anesthesia (EA)
Number of subjects: 89
Study 30222620 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia (GA)
Number of subjects: 89
Study 27780785 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal ongoing (character continues to eat)
Number of subjects: 147
Study 27780785 — intervention group
Group type: COMPARATOR
Intervention: Goal completed (character completes eating)
Number of subjects: 147
Study 26092310 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully-liquid hexavalent vaccine (DTaP-IPV-HB-PRP-T, Sanofi Pasteur MSD)
Number of subjects: 96
Study 26092310 — intervention group
Group type: COMPARATOR
Intervention: Non-fully liquid hexavalent vaccine (DTPa-HBV-IPV/Hib, GlaxoSmithKline Biologicals)
Number of subjects: 96
Study 26092310 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 96
Study 26092310 — intervention group
Group type: EXPERIMENTAL
Intervention: Fully-liquid hexavalent vaccine
Number of subjects: 96
Study 23545009 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG maintenance therapy with one third of usual dose (group I)
Number of subjects: 0
Study 23545009 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG maintenance therapy with reduced dose and decreased number of instillations (two instead of three) (group II)
Number of subjects: 0
Study 21756786 — intervention group
Group type: EXPERIMENTAL
Intervention: Food exchange serving based on glycemic load (FES + GL)
Number of subjects: 83
Study 21756786 — intervention group
Group type: COMPARATOR
Intervention: Food exchange serving (FES)
Number of subjects: 83
Study 19325013 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (BUP)
Number of subjects: 9
Study 17118319 — intervention group
Group type: EXPERIMENTAL
Intervention: HDR brachytherapy
Number of subjects: 126
Study 17118319 — intervention group
Group type: COMPARATOR
Intervention: PPI preplan
Number of subjects: 126
Study 17118319 — intervention group
Group type: COMPARATOR
Intervention: PPI postplan
Number of subjects: 126
Study 12752845 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 44
Study 12752845 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen
Number of subjects: 44
Study 12752845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 11118822 — intervention group
Group type: EXPERIMENTAL
Intervention: Essential amino acid (EAA) supplementation (average daily dose of 18.3 g of EAAs in pill form)
Number of subjects: 21
Study 11118822 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 21
Study 9146772 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine suppositories (1 g)
Number of subjects: 242
Study 9146772 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone foam (100 mg)
Number of subjects: 242
Study 7816790 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (TA) for acute treatment, 200 mg at first symptoms, repeat after 2-3 hours if needed.
Number of subjects: 0
Study 7816790 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolfenamic acid (TA) for prophylactic treatment, 300 mg sustained release or 100 mg 3 times daily.
Number of subjects: 0
Study 2905992 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol 100 mg once daily for 6 weeks
Number of subjects: 15
Study 29380267 — intervention group
Group type: COMPARATOR
Intervention: SUVN-502 200 mg single dose
Number of subjects: 0
Study 29380267 — intervention group
Group type: COMPARATOR
Intervention: SUVN-502 130 mg once daily for 7 days
Number of subjects: 0
Study 29380267 — intervention group
Group type: COMPARATOR
Intervention: SUVN-502 100 mg once daily for 14 days
Number of subjects: 0
Study 29380267 — intervention group
Group type: EXPERIMENTAL
Intervention: SUVN-502 100 mg single dose
Number of subjects: 0
Study 29380267 — intervention group
Group type: EXPERIMENTAL
Intervention: SUVN-502 50 mg once daily for 7 days
Number of subjects: 0
Study 29380267 — intervention group
Group type: EXPERIMENTAL
Intervention: SUVN-502 50 mg and 100 mg once daily
Number of subjects: 0
Study 27733377 — intervention group
Group type: COMPARATOR
Intervention: mFOLFOX-6
Number of subjects: 158
Study 27733377 — intervention group
Group type: EXPERIMENTAL
Intervention: RAM+mFOLFOX-6
Number of subjects: 158
Study 27733377 — intervention group
Group type: EXPERIMENTAL
Intervention: ICR+mFOLFOX-6
Number of subjects: 158
Study 27733377 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 158
Study 25182248 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity rosuvastatin (40 mg/day) for 13 months
Number of subjects: 103
Study 25182248 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 103
Study 23465742 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRHa
Number of subjects: 254
Study 23465742 — intervention group
Group type: COMPARATOR
Intervention: Oestrogen patches
Number of subjects: 254
Study 21270200 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal ABI (0.91-1.3)
Number of subjects: 2240
Study 21270200 — intervention group
Group type: EXPERIMENTAL
Intervention: Low ABI (<0.9)
Number of subjects: 2240
Study 21270200 — intervention group
Group type: EXPERIMENTAL
Intervention: High ABI (>1.3)
Number of subjects: 2240
Study 21270200 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncompressible artery (NC)
Number of subjects: 2240
Study 21270200 — intervention group
Group type: COMPARATOR
Intervention: Low ABI
Number of subjects: 2240
Study 21270200 — intervention group
Group type: COMPARATOR
Intervention: High ABI
Number of subjects: 2240
Study 18434900 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy for strict blood glucose control to normoglycemia
Number of subjects: 0
Study 18434900 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 0
Study 16549920 — intervention group
Group type: EXPERIMENTAL
Intervention: Leflunomide (100 mg/day loading dose for 3 days followed by 20 mg/day orally)
Number of subjects: 190
Study 16549920 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 190
Study 12517741 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) at doses of 25, 50, 125, 300, or 600 mg/wk for 20 weeks
Number of subjects: 54
Study 10719857 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal bolus injections of baclofen
Number of subjects: 11
Study 10719857 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous administration of baclofen
Number of subjects: 11
Study 10719857 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 11
Study 9175128 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with left or right hemisphere infarctions
Number of subjects: 0
Study 9175128 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study 8357287 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient interdisciplinary geriatric consultation
Number of subjects: 197
Study 8357287 — intervention group
Group type: COMPARATOR
Intervention: Control group (no geriatric consultation)
Number of subjects: 197
Study 3542445 — intervention group
Group type: COMPARATOR
Intervention: Acarbose 400 mg
Number of subjects: 5
Study 3542445 — intervention group
Group type: COMPARATOR
Intervention: Acarbose 200 mg
Number of subjects: 5
Study 3542445 — intervention group
Group type: COMPARATOR
Intervention: Acarbose 100 mg (after one week of administration)
Number of subjects: 5
Study 3542445 — intervention group
Group type: COMPARATOR
Intervention: Acarbose (all doses tested)
Number of subjects: 5
Study 28669329 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/day rosuvastatin
Number of subjects: 40
Study 28669329 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-40 mg/day rosuvastatin
Number of subjects: 40
Study 27609386 — intervention group
Group type: EXPERIMENTAL
Intervention: Easy One Adper (A1)
Number of subjects: 360
Study 27609386 — intervention group
Group type: EXPERIMENTAL
Intervention: Adper Easy One (B1)
Number of subjects: 360
Study 27609386 — intervention group
Group type: EXPERIMENTAL
Intervention: iBond SE (C1)
Number of subjects: 360
Study 27609386 — intervention group
Group type: COMPARATOR
Intervention: Phosphoric acid etching (A2, B2, C2)
Number of subjects: 360
Study 23999037 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan/Amlodipine combination (20/5mg)
Number of subjects: 276
Study 22417131 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive long-term step-down treatment program (short-term day hospital treatment followed by combined group and individual psychotherapy)
Number of subjects: 113
Study 22417131 — intervention group
Group type: COMPARATOR
Intervention: Outpatient individual psychotherapy in private practice
Number of subjects: 113
Study 20171677 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation
Number of subjects: 220
Study 20171677 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 220
Study 18242805 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee-bracing
Number of subjects: 10
Study 18242805 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle-bracing
Number of subjects: 10
Study 18242805 — intervention group
Group type: COMPARATOR
Intervention: Unbraced (normative data)
Number of subjects: 10
Study 16287075 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV testing as a primary cervical cancer screening test
Number of subjects: 0
Study 16287075 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 12966418 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care (SC) with concomitant chemotherapy
Number of subjects: 1185
Study 12966418 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care (SC) with corticosteroids
Number of subjects: 1185
Study 12966418 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care (SC) for elderly patients
Number of subjects: 1185
Study 12966418 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive care (SC) overall
Number of subjects: 1185
Study 12966418 — intervention group
Group type: COMPARATOR
Intervention: Vinorelbine
Number of subjects: 1185
Study 12966418 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin-based treatment
Number of subjects: 1185
Study 11135780 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning examination (n = 6483)
Number of subjects: 12882
Study 11135780 — intervention group
Group type: COMPARATOR
Intervention: Afternoon examination (n = 6399)
Number of subjects: 12882
Study 8787869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin given orally (500 mg) alone
Number of subjects: 26
Study 8787869 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin given orally (500 mg) plus enteral feeding (Sustacal)
Number of subjects: 26
Study 8787869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin given via gastrostomy tube (500 mg crushed in 60 ml water)
Number of subjects: 26
Study 8787869 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin given via gastrostomy tube (500 mg crushed) plus continuous enteral formula (Jevity)
Number of subjects: 26
Study 8787869 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin given via jejunostomy tube (500 mg crushed)
Number of subjects: 26
Study 8787869 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin given via jejunostomy tube (500 mg crushed) plus continuous enteral formula (Jevity)
Number of subjects: 26
Study 1454432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (CFX), 8 mg/kg once daily
Number of subjects: 110
Study 1454432 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V (PEN), 250 mg 3 times daily
Number of subjects: 110
Study 1454432 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefixime (CFX)
Number of subjects: 110
Study 1454432 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V (PEN)
Number of subjects: 110
Study 3906248 — intervention group
Group type: EXPERIMENTAL
Intervention: Naftidrofuryl 600 mg daily for six months
Number of subjects: 23
Study 3906248 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 23
Study 31923203 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention (educational handouts)
Number of subjects: 6082
Study 31923203 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention + recliner chair
Number of subjects: 6082
Study 31923203 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 6082
Study 30204953 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved platelets (CPPs)
Number of subjects: 28
Study 30204953 — intervention group
Group type: COMPARATOR
Intervention: Liquid-stored platelets (LSPs)
Number of subjects: 28
Study 26370118 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifunctional diet (MFD)
Number of subjects: 47
Study 26370118 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CD)
Number of subjects: 47
Study 24827384 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA) 300mg tablets, two times per day for six months
Number of subjects: 32
Study 24827384 — intervention group
Group type: EXPERIMENTAL
Intervention: Palmitoylethanolamide (PEA)
Number of subjects: 32
Study 24827384 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control Group B)
Number of subjects: 32
Study 23475541 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine XR
Number of subjects: 662
Study 23475541 — intervention group
Group type: COMPARATOR
Intervention: Lamotrigine IR
Number of subjects: 662
Study 20538235 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg tramadol (Group T)
Number of subjects: 60
Study 20538235 — intervention group
Group type: COMPARATOR
Intervention: 0.75 mg/kg tramadol plus 1 g of paracetamol (Group P)
Number of subjects: 60
Study 18165641 — intervention group
Group type: EXPERIMENTAL
Intervention: PCB (Bevacizumab in combination with carboplatin and paclitaxel)
Number of subjects: 224
Study 18165641 — intervention group
Group type: COMPARATOR
Intervention: PC (Carboplatin and paclitaxel)
Number of subjects: 224
Study 18165641 — intervention group
Group type: EXPERIMENTAL
Intervention: PCB
Number of subjects: 224
Study 18165641 — intervention group
Group type: COMPARATOR
Intervention: PC
Number of subjects: 224
Study 15906418 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg (Blosart, Julphar, UAE)
Number of subjects: 24
Study 15906418 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg (Cozaar, MSD, The Netherlands)
Number of subjects: 24
Study 12905137 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic infection with Borrelia burgdorferi
Number of subjects: 0
Study 10509575 — intervention group
Group type: EXPERIMENTAL
Intervention: MOS-HIV
Number of subjects: 558
Study 10509575 — intervention group
Group type: EXPERIMENTAL
Intervention: MQOL-HIV
Number of subjects: 558
Study 10509575 — intervention group
Group type: COMPARATOR
Intervention: Healthy blood donors
Number of subjects: 558
Study 8941830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac‐Fil, finished immediately
Number of subjects: 30
Study 8941830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketac‐Fil, finished after a delay
Number of subjects: 30
Study 8941830 — intervention group
Group type: EXPERIMENTAL
Intervention: Chelon‐Fil
Number of subjects: 30
Study 8941830 — intervention group
Group type: COMPARATOR
Intervention: Cervident (resin composite)
Number of subjects: 30
Study 1744385 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 N HCl infusion
Number of subjects: 19
Study 1744385 — intervention group
Group type: COMPARATOR
Intervention: Normal saline infusion
Number of subjects: 19
Study 7027708 — intervention group
Group type: EXPERIMENTAL
Intervention: Progestogen only (Lynestrenol 0.5 mg daily)
Number of subjects: 38
Study 7027708 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral contraceptive (Ethinyl oestradiol 50 μg + lynestrenol 2.5 mg)
Number of subjects: 38
Study 7027708 — intervention group
Group type: COMPARATOR
Intervention: Non-hormonal intrauterine device (IUD)
Number of subjects: 38
Study 31764994 — intervention group
Group type: EXPERIMENTAL
Intervention: Fruit diet
Number of subjects: 40
Study 31764994 — intervention group
Group type: COMPARATOR
Intervention: Invertebrate diet
Number of subjects: 40
Study 31053668 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular ultrasound (NMUS) added to electrodiagnostic testing
Number of subjects: 0
Study 31053668 — intervention group
Group type: COMPARATOR
Intervention: Electrodiagnostic testing alone
Number of subjects: 0
Study 28950844 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 20 mg/d for 2 weeks before surgery
Number of subjects: 40
Study 28950844 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 40
Study 27422275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) programme, one session every 2 weeks for 10 weeks, with telephone contact every 2 weeks
Number of subjects: 180
Study 27422275 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention, one session every 2 weeks for 10 weeks, with telephone contact every 2 weeks
Number of subjects: 180